Voteopolis | 116th-congress-H.R.5894 Bill DashBoard

| | Petition Blog | << < > >>

Introduced in House	Passed House	Introduced in Senate	Passed Senate	To President	Became Law
02/13/2020

Transparency in Prescription Drug Advertising Act

Date	Version	PDF	TXT
01/01/2111		Open
02/13/2020	Introduced in House	Open

2 1 to 12 of 2

Name	From	Date	Type
Sharice Davids	D-KS	02/13/2020	Sponsor
Elissa Slotkin	D-MI	02/13/2020	Cosponsor
Ed Perlmutter	D-CO	05/01/2020	Cosponsor
Abby Finkenauer	D-IA	02/13/2020	Cosponsor

2 1 to 12 of 4

Date	Branch	Action
02/13/2020	President	Referred to the House Committee on Energy and Commerce.Action By: House of Representatives
02/13/2020	President	Introduced in HouseAction By: House of Representatives

2 1 to 12 of 2

Summary
There is one summary for H.R.5894. View summaries Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.
Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.

Summary

There is one summary for H.R.5894. View summaries Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.

Shown Here:Introduced in House (02/13/2020) Transparency in Prescription Drug Advertising Act This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency. On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.

2 1 to 12 of 2

Congress - Bill Number	Major Title

2 1 to 12 of 0

Branch	Vote Date	Yes	No	Not Voting

2 1 to 12 of 0

Wiki

Bill TEXT Points.
This Bill has been listed with the following Subjects from Texts:
Commerce
Finkenauer) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo direct the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs

Congress

Drugs
Pricing transparency in drug advertising(a)In generalNot later than one year after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with the Commissioner of Food and Drugs and the Administrator of the Centers for Medicare & Medicaid Services, shall issue department-wide guidance requiring the list prices of drugs to be included, as appropriate, in all advertising of drugs, including by means of television, newspapers, the internet, or other media

Energy
Finkenauer) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo direct the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs

End Bill TEXT Points.

Date	Bill	Major Title

2 1 to 12 of 0

Committee Name

2 0 to 12 of 0

Subject	Type

2 1 to 12 of 0

Top

2 1 to 12 of 0